PRIMARY CEREBRAL MALIGNANT NON-HODGKINS-LYMPHOMAS - A RETROSPECTIVE CLINICAL-STUDY

被引:57
作者
BRAUS, DF
SCHWECHHEIMER, K
MULLERHERMELINK, HK
SCHWARZKOPF, G
VOLK, B
MUNDINGER, F
机构
[1] UNIV FREIBURG,NEUROCHIRURG KLIN,STEREOTAXIE & NEURONUKL MED ABT,W-7800 FREIBURG,GERMANY
[2] UNIV WURZBURG,INST PATHOL,W-8700 WURZBURG,GERMANY
关键词
PRIMARY MALIGNANT BRAIN LYMPHOMA; IMMUNOCYTOCHEMISTRY; COMPUTED TOMOGRAPHY;
D O I
10.1007/BF00833908
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In this retrospective study a series of 54 patients (seen from 1982 to 1989) with sporadic primary cerebral malignant lymphomas (PCML), which were uniformly classified with the support of immunocytochemical data, is presented. The analysis shows that on CT PCML are shown as cirumscribed, homogeneous, contrast-enhanced multifocal (70%) or solitary (30%) mass lesions within the subcortical white matter; they were found mainly close to the ventricular system or the subarachnoid space. To prove the histological diagnosis and for the purposes of differential diagnosis, low-risk CT-stereotatic biopsy is necessary and is the method of choice. Immunomorphological techniques are valuable adjuncts to confirm the histological diagnosis of PCML. In the series presented these tumours have been predominantly classified as high-grade blastic B-cell lymphomas. For this reason, this type should be regarded as the prevalent variant of malignant brain lymphomas. The evaluation of possible prognostic factors suggests that age at admission and morphological features of regression are relevant determinants of survival time. A correlation between neuroradiological evidence of a decrease in tumour size, morphological signs of regression and glucocorticoid administration has been found. Thus, patients suspected to having PCML require rapid diagnosis prior to corticosteroid administration. PCML have been shown to be radioresponsive, but not curable. Because of the lack of uniformity in management of this rare brain neoplasm, the different treatment protocols are not comparable, and hence the optimum therapy has not been satisfactorily determined. Therefore, a rational diagnostic strategy is proposed as a basis for prospective randomized long-term follow-up studies in order to evaluate different treatment modalities and to obtain more insight into the biological behaviour of primary cerebral malignant lymphomas.
引用
收藏
页码:117 / 124
页数:8
相关论文
共 44 条
  • [21] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS
    KAPLAN, EL
    MEIER, P
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) : 457 - 481
  • [22] PRIMARY CENTRAL NERVOUS-SYSTEM LYMPHOMA
    KAWAKAMI, Y
    TABUCHI, K
    OHNISHI, R
    ASARI, S
    NISHIMOTO, A
    [J]. JOURNAL OF NEUROSURGERY, 1985, 62 (04) : 522 - 527
  • [23] STEROID-INDUCED REGRESSION OF PRIMARY MALIGNANT-LYMPHOMA OF THE BRAIN
    KIKUCHI, K
    WATANABE, K
    MIURA, S
    KOWADA, M
    [J]. SURGICAL NEUROLOGY, 1986, 26 (03): : 291 - 296
  • [24] Lennert K, 1990, HISTOPATHOLOGIE NONH
  • [25] PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA - ANALYSIS OF PROGNOSTIC VARIABLES AND PATTERNS OF TREATMENT FAILURE
    MICHALSKI, JM
    GARCIA, DM
    KASE, E
    GRIGSBY, PW
    SIMPSON, JR
    [J]. RADIOLOGY, 1990, 176 (03) : 855 - 860
  • [26] MOORMEIER JA, 1990, SEMIN ONCOL, V17, P43
  • [27] Mundinger F, 1985, Acta Neurochir Suppl (Wien), V35, P70
  • [28] MORPHOLOGIC AND IMMUNOPHENOTYPIC CHARACTERIZATION OF PRIMARY BRAIN LYMPHOMAS USING PARAFFIN-EMBEDDED TISSUE
    MURPHY, JK
    OBRIEN, CJ
    IRONSIDE, JW
    [J]. HISTOPATHOLOGY, 1989, 15 (05) : 449 - 460
  • [29] NON-HODGKINS LYMPHOMA INVOLVING THE BRAIN - DIAGNOSTIC USEFULNESS OF STEREOTACTIC NEEDLE-BIOPSY IN COMBINATION WITH PARAFFIN-SECTION IMMUNOHISTOCHEMISTRY
    NAKAMINE, H
    YOKOTE, H
    ITAKURA, T
    HAYASHI, S
    KOMAI, N
    TAKANO, Y
    SAITO, K
    MORIWAKI, H
    NISHINO, E
    TAKENAKA, T
    MAEDA, J
    MATSUMORI, T
    [J]. ACTA NEUROPATHOLOGICA, 1989, 78 (05) : 462 - 471
  • [30] NEUWELT EA, 1986, CANCER, V58, P1609, DOI 10.1002/1097-0142(19861015)58:8<1609::AID-CNCR2820580805>3.0.CO